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Abstract: Background: Xpert MTB/RIF (GX) for tuberculosis (TB) diagnosis is often located in 
reference laboratories, and sputum needs to be transported using a cold chain. Transport media to 
preserve sputum are available, but performance data under programmatic conditions are limited. 
Methods: Sputum samples were collected from patients with presumptive TB in Nigeria. One 
sputum was transported in a cold chain, tested immediately with GX and cultured. One sputum 
was swabbed and stored in PrimeStore-Molecular-Transport-Medium (Primestore), and the 
remainder was stored in OMNIGene-sputum (Omnigene), kept for seven days and tested with 
GX. Results: Of 248 patients, 63 were fresh-sputum culture-positive and 56 GX-positive (sensitivity 
88.9%, 95% CI: 78.4–95.4%). Four of 185 culture-negative patients were GX-positive (specificity 
97.8%, 94.6–99.4%). Omnigene GX and Primestore GX were positive in 56/62 (90.3%, 80.1–96.4%) 
and 49/62 (79.0%, 66.8–88.3%) culture-positive, respectively, and 1/185 (99.5%, 97.0–100.0%) and 
3/185 (98.4%, 95.3–99.7%) were culture-negative patients. 14 Human Immunodeficiency Virus 
(HIV)-infected and 44 HIV-uninfected patients were culture-positive. Omnigene and Primestore 
detected 12/14 (85.7%, 57.2–98.2%) and 5/14 (35.7%, 12.8–64.9%) HIV-infected and 41/44 (93.2%, 
81.3–98.6%) HIV-uninfected culture-positive patients. Interpretation: Omnigene stored and fresh 
sputum samples had similar GX results. The GX results of Primestore-stored samples were similar 
to those found in the fresh sputum of non-HIV infected patients, but GX-positivity was lower in 
HIV-infected patients. This was likely due to the lower amount of bacilli collected by the swab and 
transferred to PrimeStore.  
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1. Introduction 
Tuberculosis (TB) is the leading cause of death due to a single infectious agent globally [1]. 
National TB Programme (NTP) strategies address this major public health threat by increasing the 
detection of symptomatic individuals and initiating early treatment. The World Health 
Organization’s (WHO) End TB strategy and the Stop TB Partnership’s Global Plan to End TB have 
set ambitious targets for the response to TB, including a 90% reduction in TB incidence by 2035 
[2,3]. Meeting these targets will require identifying and testing many more individuals and 
expanding the reach of tests to health centres without diagnostic facilities. WHO recommends that 
countries aim to test all people with presumptive TB with Xpert MTB/RIF (GX), to improve the 
detection and accuracy of TB diagnosis including drug resistance. GX is a molecular test that is 
usually available in reference or district laboratories [4,5], due to its power and infrastructure needs 
and machine costs. Expanding access to this test frequently requires the referral of patients or the 
transport of sputum to testing centres. Sample transportation requires refrigeration to maintain the 
biological integrity of the sample and prevent bacterial and fungal proliferation, resulting in a 
decreased culture positivity. Furthermore, although archived clinical samples kept frozen can be 
later tested with GX with minimal or no loss of sensitivity, data on the performance of GX in 
samples that have been transported at ambient temperature without preserving reagents are not 
available in the public domain. 
In Nigeria, GX is mostly stationed in district hospitals, Human Immunodeficiency Virus HIV  
clinics, selected health centres and mobile vans. Despite the existing efforts to establish sputum 
transportation network (such as the ‘Riders for Health’, operating in eight states), these networks 
are still insufficient to cover the demand for health services. Although data on the time required to 
transport samples are poorly documented, a review of samples received in our laboratory, Zankli 
Research Centre, indicated that samples referred from the Northern Region of the country are 
processed within a median of six days, and 25% are processed within nine days of sample 
collection. 
Implementing a cold chain incurs substantial costs and can be especially challenging in rural 
areas. The development of sputum transport reagents that eliminate the need for a cold chain 
during transit could reduce the cost and complexity of sample transportation. One of these 
reagents, OMNIGene-sputum (Omnigene, DNA Genotek Inc., Canada), is allegedly able to 
decontaminate and liquefy sputum, whilst preventing sample degradation for up to eight days at 
ambient temperature [6]. A second reagent, PrimeStore Molecular Transport Medium (Primestore, 
Longhorn Vaccines & Diagnostics, US) has been reported to inactivate Mycobacterium tuberculosis 
(MTB) and preserve nucleic acids at ambient temperature, for downstream testing [7]. The 
inactivation of MTB would improve the biosafety of the laboratory and the transport and handling 
of samples by staff members. Both solutions have been reported to be compatible with molecular 
tests, including GX [8,9]. Although studies have reported good performance characteristics, most 
reports include small numbers of samples, typically less than 100 participants, and are sponsored 
by the manufacturers. 
We report here an independent head-to-head evaluation of the effectiveness of both Omnigene 
and Primestore for GX testing conducted in Abuja, Nigeria, under operational conditions. 
2. Methods 
We enrolled consecutive adults with signs and symptoms of presumptive pulmonary TB 
attending TB diagnostic clinics at district hospitals within Abuja, as well as patients that had been 
referred to the TB clinics for diagnosis. Patients receiving TB treatment or who had been treated for 
TB in the previous two years were excluded. Participants were asked to provide two sputum 
samples on the day of consultation, with the first sample taken on the spot and the second sample 
approximately 1 h after the first specimen [10]. One sample was transported in a cold box (called 
fresh sputum), split into two equal samples after vortexing, tested using GX within 24 h and 
cultured using Lowenstein–Jensen (LJ) solid media in two tubes at the laboratory. LJ was conducted 
using the modified Petroff's method and an N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) 
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solution as the digesting and decontaminating agent. The other sample was used for testing the 
samples stored in Primestore and Omnigene solutions. The samples were not labelled as first or 
second and were not processed in a particular order, to minimise potential differences in bacterial 
loads. However, we did not assess the bacterial load distribution in the two sputum cups. For 
Primestore, a swab was swirled five times through the sputum sample, collecting between 0.1 and 
0.2 mL of sputum; placed in the Primestore collection tube; and vortexed to mix the liquid with the 
sputum. For Omnigene, an equal volume of the Omnigene kit solution was added to the remainder 
of the sputum sample. Both samples were then transferred to Zankli Research Centre, Bingham 
University, without refrigeration, and stored for seven days in a room without air conditioning and 
maximum temperatures ranging from 30 to 37 °C, to mimic the circumstances of field storage and 
transportation. After seven days, the Omnigene-stored samples were transferred from the cup to a 
conical tube, vortexed in order to become fully liquid and centrifuged at 3800g for 20 min. The 
supernatant was gently poured off without disturbing the sediment, which was then resuspended 
in sterile Phosphate Buffered Saline for Xpert testing. For Primestore, we transferred 0.7 mL of the 
"blend" of PrimeStore and sputum into 1.4 mL of the Xpert reagent and transferred the total 2.1 mL 
volume into the Xpert cartridges. Both samples were then tested with GX and compared with the 
GX results obtained with the fresh sample and against the culture. The culture was considered the 
reference standard to estimate the sensitivity, specificity (with 95% confidence intervals, 95% CI) 
and concordance of GX positivity across the three methods. However, as solid cultures are known 
to have lower sensitivity than liquid cultures, we also used Kappa statistics to describe the level of 
agreement between the Xpert results obtained with the three approaches. GX semiquantitative 
grades were used to reflect differences in bacilli DNA concentrations between the fresh and stored 
specimens. The sample size was estimated assuming a sensitivity of 0.75 and 070 of GX to identify 
culture-positive individuals with paired fresh and stored sputum samples with a specificity of 0.95 
for both, an expected 20% of culture-positive patients and an expected Kappa of 85%. The study 
would require a sample size of 202 individuals to achieve a power of 80% and a significance of 5%. 
2.1. Ethical Approval 
The study was approved by the Health Research Ethics Committees of the Liverpool School of 
Tropical Medicine, UK, and the Federal Capital Territory, Nigeria (protocol numbers 17–014 and 
FHREC/2017/01/63/09-08-17, respectively). Patients attending the centres were asked to read and 
confirm they had understood the study information leaflets and underwent consent procedures. 
Individuals were included if they willingly provided written informed consent to participate. The 
corresponding author had full access to all the data included in the study and took responsibility 
for the integrity of the data and the accuracy of the data analysis. The sample size was estimated 
assuming a sensitivity of 0.75 and 070 of GX to identify culture-positive individuals with paired 
fresh and stored sputum samples, respectively, with a specificity of 0.95 for both, an expected 20% 
of culture-positive patients and a Kappa of 85%. The study would require a sample size of 202 
individuals to achieve a power of 80% and a significance of 5%. 
3. Results 
A total of 262 patients were enrolled and 248 (95%) had valid culture results. Of these, 63 
(25.4%) were culture-positive and 185 culture-negative (Table 1). GX in fresh sputum detected 56 of 
63 culture-positive samples (sensitivity 88.9%, 95% CI: 78.4–95.4%). Sixty-two of the 63 culture-
positive patients were also tested with GX, using the Omnigene-stored and Primestore-stored 
samples. Both sets of samples were GX-positive in 56 samples (sensitivity 90.3%, 95% CI: 80.1–
96.4%) and 49 samples (sensitivity 79.0%, 95% CI: 66.8–88.3%) respectively. The sensitivity using 
Primestore was lower when compared with the fresh sample, but this was not statistically 
significantly (McNemar’s test, p = 0.070). GX in the 185 culture-negative patients was positive in 
five patients, including four fresh samples (specificity 97.8%, 95% CI: 94.6–99.4%), one Omnigene-
stored sample (specificity 99.5%, 95% CI: 97.0–100.0%) and three Primestore-stored samples (98.4%, 
95% CI: 95.3–99.7%). One of these culture-negative samples was positive for all GX tests (fresh GX, 
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Omnigene GX and Primestore GX), suggesting that the culture may have failed to identify the 
bacteria. There were also no statistically significant differences in specificity between the three 
methods. 
HIV status was known for 59 culture-positive patients, with 14 being HIV-infected and 45 HIV-
uninfected. GX was positive in 12 fresh sputum samples (sensitivity 85.7%, 95% CI: 57.2–98.2%), 12 
Omnigene-stored samples and five Primestore-stored samples (sensitivity 35.7%, 95% CI: 12.8–
64.9%) of the 14 HIV-infected culture-positive patients. Among the 45 culture-positive HIV-
uninfected patients, GX was positive in 41/45 fresh sputum samples (sensitivity 91.1%, 95% CI: 
78.8–97.5%), 41/44 Omnigene-stored samples and 41/44 Primestore-stored samples (sensitivity 
93.2%, 95% CI: 81.3–98.6%, respectively). 
GX MTB semiquantitative grades obtained using fresh, Omnigene-stored and Primestore-
stored samples are shown in Figure 1. Omnigene-stored sputum had higher GX grades than fresh 
sputum in 14 (21%) samples, similar grades in 34 (51%) samples and lower grades in 19 (28%) 
samples. In comparison, Primestore-stored samples had higher GX grades than fresh sputum in 
four (6%) samples, similar grades in 29 (43%) and lower grades in 35 (51%).  
The agreement between GX conducted in fresh and stored samples is shown in Table 2. The 
overall agreement between fresh and Omnigene GX was 98.4% (Kappa 0.948, 95% CI: 0.903–0.993) 
and 94.7% between fresh and Primestore GX (Kappa 0.850, 95% CI: 0.774–0.926), indicating a high 
level of agreement. However, six culture-positive samples had concomitant fresh, Omnigene and 
Primestore GX negative results, suggesting that the DNA concentration may have been low and 
was missed by all GX tests. One culture-positive patient was fresh GX-negative but Omnigene and 
Primestore GX-positive. Among culture-negative samples, one sample was fresh and Omnigene 
and Primestore GX-positive, suggesting that this infection may have been missed by the culture, 
and a further three samples were culture-negative and fresh GX-positive but Omnigene and 
Primestore GX-negative, which is difficult to interpret. 
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Figure 1. Xpert semiquantitative results of fresh, Omnigene-stored and Primestore-stored sputum 
specimens. 
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Table 2. Agreement of fresh sputum and Omnigene-stored and Primestore-stored Xpert MTB/RIF by 
culture. 
Culture Positive Negative  
 fresh Xpert  fresh Xpert   positive  negative  positive  negative  Kappa (95% CI) 
Omnigene 
Xpert 
positive 55 1 1 0 0.948 (0.903–0.993) negative 0 6 3 181 
Primestore 
Xpert 
positive 48 1 1 2 0.850 (0.774–0.926) negative 7 6 3 178 
4. Discussion 
Our study adds important new information to a sparse evidence base on the role of sample 
preservation media in TB diagnosis. Sputum storage using Omnigene for one week in the absence of a 
cold chain had little impact on the sensitivity and specificity of GX. However, storing sputum with 
Primestore under the same conditions led to a lower, but not statistically significant, GX positivity among 
samples from HIV-infected individuals, who are more likely to have paucibacillary TB.  
Effective and resilient sputum transport systems are needed to increase access to WHO-
recommended diagnostics for TB. These systems need to be easy to implement at a low cost and effective 
in preserving the integrity of the sputum, as samples might not be immediately collected, might travel 
long distances and might have to wait for testing at the destination laboratory. Methods that do not need a 
cold chain would be of particular interest to NTPs with limited resources and large rural area populations, 
where the provision of cold chain transport systems are prohibitively expensive or unavailable. The ability 
to safely store samples during transport, avoiding the wastage of GX cartridges and reducing the number 
of false-negative tests due to poor sample quality, could have a major effect in improving case detection 
[11] and in the detection of drug resistance by facilitating testing with GX to obtain a RIF resistance 
reading. Although poor transport conditions increase culture contamination and decrease positivity, there 
is a paucity of data describing whether the same deleterious changes occur with nucleic acids for GX 
testing, and there are no studies comparing transport products versus no product, which makes it difficult 
to disaggregate the additional effect of the product itself.  
Omnigene was developed to preserve MTB cells for culture, with a reported viability of eight days 
[12]. Data on the use of Omnigene for downstream culture are mixed, however, with some studies 
reporting a reduced positivity when compared with the standard NALC-NaOH [13] and others reporting 
an equivalent performance [14]. Previous smaller studies have shown Omnigene to be compatible with 
molecular diagnostics such as GX [9], and our findings confirm that testing Omnigene-preserved samples 
was as accurate as directly testing fresh sputum samples, with minimal change in the cycle threshold (CT) 
values obtained. An important consideration for Omnigene, however, is the need to centrifuge to obtain a 
concentrated pellet, as this would prevent its use at peripheral sites, where centrifuges are often 
unavailable. A further issue is its cost, which is estimated at USD 2.84 [6] per sample. Because the 
Omnigene fluid needs to be added when the sputum is collected, this is likely to be the minimum cost, as 
health centres need to stock larger amounts in preparation for the number of sputum samples likely to be 
collected. Health economic studies are required to determine the cost-benefit of implementing Omnigene 
within TB programs.  
Primestore was primarily designed to preserve nucleic acids for molecular testing, rather than 
preserving cells for culture, and contains reagents to lyse mycobacteria, protecting nucleic acids from 
nuclease-mediated degradation [7]. Samples preserved in Primestore have been utilised for next 
generation sequencing [15] to identify drug-resistant mutations. This indicates their applicability to 
downstream genomics that require a level of nucleic acid integrity. In this study, sputum preserved with 
this solution resulted in lower GX semiquantitative grades and a higher proportion of false-negative 
samples in HIV-infected patients. As the reduced sensitivity was observed among HIV-infected 
individuals, it is likely that the smaller volume of sputum collected through the swab resulted in a lower 
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bacillary load. Moreover, it may also result in a reduced reliability of Primestore when testing specimens 
with GX in HIV-infected patients, compromising the usefulness of this sputum preservation method in 
some southern African populations. Longhorn Vaccines and Diagnostics, Primestore’s manufacturer, has 
recognised this issue and currently recommends testing clinical specimens using a proprietary 
quantitative polymerase chain reaction (qPCR) assay. 
We acknowledge that the study has several limitations. These include the unavoidable comparison of 
test performances using results obtained from different samples, which may have masked natural 
variations in bacilli loads among the sputum cups. We also used an LJ solid culture as the reference 
standard. LJ has lower sensitivity than liquid culture but was used because the latter is more prone to 
contamination in a study setting. Its use may have resulted in missing patients with microbiologically 
confirmed TB, and this may well be the case among participants with negative culture and multiple GX-
positive results. Furthermore, although the study included a larger number of samples than those of 
previous studies, it was not powered to identify differences between subgroups with low frequencies. 
This is specifically pertinent with regard to the subgroup of patients co-infected with HIV, as the number 
of participants (n = 14) was too small to demonstrate statistical differences.  
Furthermore, as Omnigene was developed to preserve MTB cells for culture, with a reported viability 
of eight days, it would have been desirable to test for culture at the seventh day as well, to confirm its 
performance for both GX and the culture. Moreover, the study aimed to evaluate the effectiveness of both 
Omnigene and Primestore for GX and shows that the results are similar to a GX test on a fresh sample. 
Although we opted for the comparison at day 1 and not at day 7, we failed to compare all tests at equal 
time intervals, which could have generated further evidence regarding when and where to use these 
reagents.  
5. Conclusion  
This study demonstrates that Omnigene has the potential to facilitate a cold-chain-free transport 
system for the collection of sputum for GX testing. Further studies are needed to identify logistics and 
operational issues and cost-effectiveness when implemented in areas with low access to diagnosis to 
inform a potential large-scale implementation. These products should also be studied with specimens that 
require downstream culture, as transport can affect culture results to a higher degree than GX testing. 
Specifically, evidence is needed to document Omnigene’s value for testing specimens collected from drug-
resistant TB patients, for treatment monitoring and for the diagnosis of paucibacillary smear-negative TB.  
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